This is a summary of the European public assessment report (EPAR) for Copalia HCT. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Copalia HCT. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.
Therapeutic Area (MeSH)
N/AATC Code
C09DX01
ATC Item
valsartan, amlodipine and hydrochlorothiazide
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Copalia HCT
Medicine Name
Copalia HCT
Aliases
N/ANo risk management plan link.
